WuXi Biologics & WuXi Vaccines
WuXi Biologics overview
WuXi Biologics, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, is investing €325 million in a new biopharmaceuticals contract manufacturing facility in Dundalk, Co. Louth. Located mid-way between Dublin and Belfast, the facility is less than an hour’s drive from Ireland’s two largest cities.
This highly significant investment will provide a valuable employment boost for the region, leading to the creation of 400 jobs when in full production (Scheduled for 2021). The jobs at the facility will range from manufacturing to technical and quality assurance roles as well as associated administration positions. When completed, WuXi Biologics Ireland will become one of the world’s largest facilities using single-use bioreactor technology
WuXi Vaccines overview
WuXi Vaccines, a subsidiary of WuXi Biologics, focuses on human vaccine discovery, development and manufacture. An exciting new addition to the WuXi Biologics family, WuXi Vaccines will bring to the global vaccine industry the world-class integrated platforms and CDMO business model on which WuXi Biologics reputation is based.
In development is an integrated vaccine manufacturing facility with 240 million US Dollar investment, including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC), dedicated to manufacturing our partner’s vaccine products for the global market. It is expected to be operational in 2022. It will bring 200 additional new jobs to Dundalk town over five years.